Project Grant R01HD123217
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded $445,500 to Cincinnati Children's Hospital Medical Center on July 25, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct preclinical research on microRNA-mediated regulation of IL-17A-associated neurodevelopmental defects induced by maternal immune activation. The...
- The National Institute of Mental Health awarded the University of California, Davis $171,018 on September 25, 2025, under the Mental Health Research Grants program (CFDA 93.242) to support a predoctoral fellowship dissertation investigating brain aging in adults with autism spectrum disorder. The fellow will characterize age-related changes in neuroimmune profiles, immune cell phenotypes, and neuronal inflammation throughout adulthood in individuals with autism spectrum disorder. The research...
- The National Institute of Mental Health awarded the University of California, Davis $123,498 under the Mental Health Research Grants program (CFDA 93.242) on June 5, 2026, to support research improving the quality and acceptability of autism services. The award is structured as a K99 (Pathway to Independence) Project Grant, supporting investigation into the safety, validity, and ethics of early intervention approaches for autism in light of concerns raised by the neurodiversity movement and...
- The National Institute of Neurological Disorders and Stroke, an institute of the National Institutes of Health, awarded The Regents of the University of California, San Francisco $205,200 on August 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research into the role of microglia in cortical interneuron development in genetic and environmental disruptions associated with autism spectrum disorder. The work...
- The National Institute of Mental Health awarded The Research Foundation For The State University Of New York $802,543 on June 10, 2026, under the Mental Health Research Grants program (CFDA 93.242) to dissect the role of astrocytes in mediating adverse outcomes of maternal immune activation. The project grant funds research examining how prenatal infections triggering maternal immune activation contribute to neurodevelopmental disorders including schizophrenia, autism spectrum disorder, and...
- Federal Grant Award Summary The Eunice Kennedy Shriver National Institute of Child Health and Human Development awarded a $165,000 Project Grant to Massachusetts General Hospital (The General Hospital Corporation) under the Child Health and Human Development Extramural Research program (CFDA 93.865) for the period August 1, 2025 through July 31, 2027. The research project investigates the cerebrospinal fluid (CSF) system in children with autism spectrum disorder (ASD), with particular focus on...
- The National Institute of Child Health and Human Development awarded $765,377 to The Children's Hospital of Philadelphia on June 17, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to establish clinical trial readiness of magnetoencephalography (MEG) biomarkers in children across the autism spectrum. The award funds a 12-week repeated scanning design study to standardize and validate two leading MEG measures—diminished and delayed auditory evoked...
- The National Institute of Child Health and Human Development awarded the University of California, Davis $702,556 on May 15, 2026, under the Child Health and Human Development Extramural Research Projects program (CFDA 93.865) to model neurodevelopmental risk of imbalanced micronutrient supply in cerebral organoids. The research addresses a gap in understanding potentially detrimental effects of high folic acid (FA) intake on fetal neurodevelopment. While FDA-mandated grain fortification with FA...
- The National Institute of Child Health and Human Development awarded New York University $245,782 on February 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to establish a cohort of 90 high-risk pregnancies and investigate how maternal immune activation alters fetal and infant brain development across the birth transition period. The research integrates advanced neuroimaging, maternal inflammatory biomarkers, and objective infant behavioral...
- The National Institute of Child Health and Human Development awarded $990,342 to the Regents of the University of Michigan on August 13, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct research on intergenerational programming of neurodevelopmental disorders. The research constructs a multigenerational cohort of more than 1.4 million grandmaternal-parental-offspring triads using linked nationwide Swedish registries to examine associations...
The National Institute of Child Health and Human Development awarded the University of California, Davis $683,451 on September 1, 2026, to conduct longitudinal neuroimaging research on maternal autoantibody-related autism (MAR) as a biologically defined autism spectrum disorder subtype, under CFDA 93.865 (Child Health and Human Development Extramural Research). The recipient will investigate autism-related maternal autoantibodies and immune dysregulation by analyzing the Autism Phenome Project–Autism (APP-A) longitudinal cohort, which comprises 395 autistic children (285 male, 128 female) and 166 typically developing children (92 male, 74 female) ages 2–18 years with multimodal neuroimaging, deep phenotyping, and banked maternal and child plasma samples. MAR is defined by maternal IgG antibodies reactive with fetal brain proteins (CRMP1, CRMP2, STIP1, GDA, NSE, YBOX) during gestation; prenatal exposure occurs in up to 20 percent of autistic children and is entirely absent in non-autistic children. Preliminary neuroimaging indicates MAR children display extreme early brain overgrowth and selective frontal lobe enlargement, and preclinical models demonstrate that MAR antibodies cross the placenta, bind fetal brain, and produce sex-specific alterations in brain growth, white matter, and network coordination. The award funds comprehensive human imaging studies to close the translational gap between preclinical mechanistic understanding and clinical outcomes. Performance occurs at Sacramento, California, with a period of performance through May 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $683.5k | 9/3/26 |